

OCT 29 2002
PATENT & TRADEMARK OFFICE

FILE

Attorney Docket No. 59150-8008.US00

\$ 1600
#20
pw

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Box AF Washington, D.C., 20231, on:

Date: October 22, 2002

By: Lynnea B. Anderson
Lynnea B. Anderson

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: ISHIKAWA *et al.*
APPLICATION No.: 09/555,704
FILED: JUNE 2, 2000
FOR: ENHANCED IMMUNOGEN FOR INACTIVATED VACCINE
FOR INFECTION WITH JAPANESE ENCEPHALITIS
VIRUSES AND PROCESS FOR PRODUCING THE SAME

EXAMINER: BROWN, S.
ART UNIT: 1648
CONFIRMATION No.: 9123

RECEIVED
NOV 05 2002
TECH CENTER 1600/2900

Supplemental Information Disclosure Statement After Final Action or Notice of Allowance but Before Payment of Issue Fee – 37 CFR 1.97(d)

Assistant Commissioner for Patents
Box AF
Washington, D.C. 20231
Sir:

1. Timing of Submission
This information is being filed *after* a final Office action or a Notice of Allowance, whichever occurs first, but before payment of the Issue Fee.
2. Petition – 37 CFR 1.97(d)
Applicant petitions the Patent and Trademark Office to accept this Information Disclosure Statement in light of the certification under 37 CFR 1.97(e) below, and payment of the fee under 37 CFR 1.97(d)(2).
3. Cited Information
 - ☒ Copies of the following references are enclosed:
 - ☒ The reference cited
 - ☐ References marked by asterisks
 - ☐ The following:
 - ☐ Copies of the following references can be found in parent U.S. Application No. :
 - ☐ All cited references
 - ☐ References marked by asterisks
 - ☐ The following:

10/30/2002 AWONDAF1 00000083 09555704

01 FC:1806

180.00 OP

4. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

5. Certification Under 37 CFR 1.97(e) (check one)

☒ In accordance with 37 CFR 1.97(e)(1), the undersigned hereby states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to this filing of this statement; or

☐ In accordance with 37 CFR 1.97(e)(2), the undersigned hereby states that no item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c), more than three months prior to the filing of this statement.

6. Fee Payment – 37 CFR 1.97(d)(2)

☒ Enclosed is a check in the amount of \$180 covering the fee due.


☒ Please charge any underpayment or credit any overpayment for timely filing of this paper to Deposit Account No. 50-2207.

7. Patent Term Adjustment (37 CFR 1.704(d))

☒ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR §1.56(c) more than thirty days prior to the filing of this statement. 37 CFR §1.704(d).

Respectfully submitted,
Perkins Coie LLP

Date: October 22, 2002


Jacqueline F. Mahoney
Registration No. 48,390

Correspondence Address:

Customer No. 22918

Tel: (650) 838-4410

Fax: (650) 838-4350